Phone: 959-333-0983
Phone: 959-333-0983
$74.99
This item has been third-party tested by accredited U.S. laboratories and confirmed to meet a minimum purity of 98% through rigorous verification standards.
$74.99
Synthetic Thymosin Beta-4 protein, an actin-binding regulatory peptide — lyophilized powder. Supplied by Research Chemical exclusively for laboratory research use.
Lyophilized powder, sterile glass vial.
Independently analyzed by an accredited third-party lab.
43-amino-acid actin-binding protein, confirmed by mass spectrometry.
Supplied exclusively for laboratory investigation.
| Compound Class | Synthetic Actin-Binding Regulatory Protein |
|---|---|
| Form | Lyophilized powder, sterile glass vial |
| Amount per Vial | 5 mg |
| CAS Number | 77591-33-4 |
| Chemical Formula | C212H350N56O78S |
| Molar Mass | ~4963 g/mol |
| Synonyms | TB-500, Thymosin Beta-4, Tβ4 |
| Verified Purity | Batch-tested to 98% (HPLC) |
For laboratory research use only. Not for human or animal consumption.
Each peptide batch is analyzed by an accredited third-party laboratory before it ships.
Most recent batch certificate of analysis, issued by MZ Biolabs. Click to view full size on the certificates page.
Every batch sold by Research Chemical is independently analyzed before it ships.
This product is an investigational compound and is not a drug, food, dietary supplement, or cosmetic. It is not approved for human or animal use, and it is unlawful to market it for that purpose.
TB-500 (Thymosin Beta-4) is prohibited by the World Anti-Doping Agency (WADA) at all times under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics).
Research Chemical makes no representations regarding the safety or effects of this compound in humans or animals.
Research Chemical is a chemical supplier, not a medical provider. We do not condone or encourage consumer use of research compounds.
Research use only. All products sold by Research Chemical are intended exclusively for laboratory research and development. They are not for human or animal consumption. These statements have not been evaluated by the U.S. Food and Drug Administration, and these products are not intended to diagnose, treat, cure, or prevent any disease.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Research Chemical products are third-party tested by MZ Biolabs, an independent laboratory based in Arizona. Each batch is analyzed to ensure accuracy, purity, and that all specifications are met.
Each Certificate of Analysis includes:
By purchasing from ResearchChemical.com, you acknowledge that you are acquiring research chemicals intended solely for scientific investigation.
These products:
ResearchChemical.com assumes no liability for misuse, improper handling, or use outside of controlled laboratory settings.
1. Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005 Aug;11(8): 354-61.
2. Post A, Al-Rawi M, Sumitran-Holgersson S. In vivo tissue repair activity of thymosin beta-4 in wound healing. Annals of the New York Academy of Sciences. 2007 Sep;1112: 177-81. doi: 10.1196/annals.1415.019.
3. Hinkel, R., El-Aouni, C., Olson, T., Horstkotte, J., Mayer, S., Müller, S., … & Kupatt, C. (2008). Thymosin β4 is an essential paracrine factor of embryonic endothelial progenitor cell–mediated cardioprotection. Circulation, 117(17), 2232-2240.
4. Belsky, J. B., Rivers, E. P., Filbin, M. R., Lee, P. J., & Morris, D. C. (2018). Thymosin beta 4 regulation of actin in sepsis. Expert opinion on biological therapy, 18(sup1), 193-197.
5. Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004 Apr;432(7016): 466-72. doi: 10.1038/nature03000.
6. Goldstein, A. L., Hannappel, E., Sosne, G., & Kleinman, H. K. (2012). Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert opinion on biological therapy, 12(1), 37-51.
7. Sosne, G., Rimmer, D., Kleinman, H. K., & Ousler, G. (2016). Thymosin beta 4: a potential novel therapy for neurotrophic keratopathy, dry eye, and ocular surface diseases. Vitamins and hormones, 102, 277-306.
8. Smart, N., Risebro, C. A., Melville, A. A., Moses, K., Schwartz, R. J., Chien, K. R., & Riley, P. R. (2007). Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature, 445(7124), 177-182.
Join our insider list for the latest research insights, product releases, and special offers—delivered straight to your inbox.